347976-06-1

Upstream product

• 192443-41-7 1-(4-bromophenyl)-6-methoxy-3,4-dihydroisoquinoline 
• 586-75-4 4-chlorobenzoyl chloride 
• 586-76-5 4-Bromobenzoic acid 
• 347976-00-5 1-(4-Bromophenyl)-6-methoxy-3,4-dihydroisoquinoline hydrochloride 
• 1122-91-4 4-bromo-benzaldehyde 
• 192443-40-6 4-bromo-N-[2-(3-methoxy-phenyl)-ethyl]-benzamide 
• 2039-67-0 2-(3-methoxyphenyl)-1-ethanamine 

Downstream Products

• 347979-32-2 1-[1-(4-bromophenyl)-6-methoxy-3,4-dihydro-1H-isoquinolin-2-yl]-2,2,2-trifluoroethanone 
• 1349743-80-1 (RS)-1-(4'-bromophenyl)-6-methoxy-1,2,3,4-tetrahydroisoquinoline-2-sulfonamide 

Relevant academic research and scientific papers

Synthesis and biological profile of new 1,2,3,4-tetrahydroisoquinolines as selective carbonic anhydrase inhibitors

In a previous paper we identified several 1-aryl-6,7-dimethoxy-1,2,3,4- tetrahydroisoquinoline-2-sulfonamides that displayed inhibitory effects toward selected carbonic anhydrase isozymes at micromolar concentration. In order to deepen the structure-activ

3D pharmacophore models for 1,2,3,4-tetrahydroisoquinoline derivatives acting as anticonvulsant agents

A 3D pharmacophore model predicting anticonvulsant activity was obtained for a series of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives recently disclosed as a new class of non-competitive AMPA receptor antagonists. The training set included 17

Tetrahydroisoquinolines as subtype selective estrogen agonists/antagonists

Two series of 6-hydroxy and 7-hydroxy tetrahydroisoquinolines were prepared. Evaluating a range of C-1, C-4, and N-substituents led to the discovery of ER α and ER β selective analogs.

Tetrahydroisoquinoline compounds as estrogen agonists/antagonists

This invention relates to compounds useful for treating or preventing obesity, breast cancer, osteoporosis, endometriosis, cardiovascular disease, prostatic disease, and the like, and to pharmaceutical composition, methods, and kits comprising such compou